| Janah Aji, MD | |
|
900 Centennial Blvd, Building 2 Suite 202, Voorhees, NJ 08043-4637 | |
| (856) 325-6700 | |
| (856) 325-6702 |
| Full Name | Janah Aji |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 45 Years |
| Location | 900 Centennial Blvd, Voorhees, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629164918 | NPI | - | NPPES |
| 0369546000 | Other | NJ | AMERIHEALTH HMO |
| 060047034 | Other | NJ | RSAILROAD MEDICARE |
| 3K5948 | Other | NJ | HEALTHNET, INC |
| 551668 | Other | NJ | AMERIHEALTH PPO PABS |
| CA0000169 00 | Other | NJ | AMERICHOICE |
| 0198224 | Other | NJ | CIGNA |
| 1066074 | Other | NJ | HORIZON NJ HEALTH |
| 1491504 | Medicaid | NJ | |
| 852690 | Other | NJ | AETNA US HEALTHCARE |
| 18925 | Other | NJ | UNIVERSITY HEALTH PLAN |
| P430257 | Other | NJ | OXFORD HEALTH PLAN |
| 186000504 | Other | NJ | UNITED HEALTH CARE |
| 1860005 | Other | NJ | UNITED HEALTH CARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cooper University Hospital | Camden, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cmc Department Of Medicine Group Pa | 2163335878 | 329 |
News Archive
A team from the Universitat Politècnica de València (UPV), the Universitat de València (UV) and the Aiken Ophthalmic Clinic (through its Research Foundation) have designed and assessed in their laboratories a new groundbreaking implant, the only one in its kind, to correct presbyopia.
Researchers around the globe are working on turning microRNAs, over 5,000 of which already have been identified, into novel drugs for a wide range of applications, reports Genetic Engineering & Biotechnology News (GEN). These noncoding single-stranded RNAs act through binding to complementary mRNA sequences, thus preventing their translation into protein or accelerating mRNA breakdown, according to the March 15 issue of GEN.
The first clinical trial in South Africa and on the continent for a Covid-19 vaccine was announced today, 23 June 2020, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
› Verified 6 days ago
| Entity Name | Cmc Department Of Medicine Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386682094 PECOS PAC ID: 2163335878 Enrollment ID: O20050104000343 |
News Archive
A team from the Universitat Politècnica de València (UPV), the Universitat de València (UV) and the Aiken Ophthalmic Clinic (through its Research Foundation) have designed and assessed in their laboratories a new groundbreaking implant, the only one in its kind, to correct presbyopia.
Researchers around the globe are working on turning microRNAs, over 5,000 of which already have been identified, into novel drugs for a wide range of applications, reports Genetic Engineering & Biotechnology News (GEN). These noncoding single-stranded RNAs act through binding to complementary mRNA sequences, thus preventing their translation into protein or accelerating mRNA breakdown, according to the March 15 issue of GEN.
The first clinical trial in South Africa and on the continent for a Covid-19 vaccine was announced today, 23 June 2020, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
› Verified 6 days ago
| Entity Name | Inspira Health Network Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922177856 PECOS PAC ID: 4880797570 Enrollment ID: O20070319000280 |
News Archive
A team from the Universitat Politècnica de València (UPV), the Universitat de València (UV) and the Aiken Ophthalmic Clinic (through its Research Foundation) have designed and assessed in their laboratories a new groundbreaking implant, the only one in its kind, to correct presbyopia.
Researchers around the globe are working on turning microRNAs, over 5,000 of which already have been identified, into novel drugs for a wide range of applications, reports Genetic Engineering & Biotechnology News (GEN). These noncoding single-stranded RNAs act through binding to complementary mRNA sequences, thus preventing their translation into protein or accelerating mRNA breakdown, according to the March 15 issue of GEN.
The first clinical trial in South Africa and on the continent for a Covid-19 vaccine was announced today, 23 June 2020, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Janah Aji, MD 1 Federal St # 100, Camden, NJ 08103-1088 Ph: (856) 356-4924 | Janah Aji, MD 900 Centennial Blvd, Building 2 Suite 202, Voorhees, NJ 08043-4637 Ph: (856) 325-6700 |
News Archive
A team from the Universitat Politècnica de València (UPV), the Universitat de València (UV) and the Aiken Ophthalmic Clinic (through its Research Foundation) have designed and assessed in their laboratories a new groundbreaking implant, the only one in its kind, to correct presbyopia.
Researchers around the globe are working on turning microRNAs, over 5,000 of which already have been identified, into novel drugs for a wide range of applications, reports Genetic Engineering & Biotechnology News (GEN). These noncoding single-stranded RNAs act through binding to complementary mRNA sequences, thus preventing their translation into protein or accelerating mRNA breakdown, according to the March 15 issue of GEN.
The first clinical trial in South Africa and on the continent for a Covid-19 vaccine was announced today, 23 June 2020, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
› Verified 6 days ago
Kumar Rajagopalan, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 900 Centennial Blvd Ste M, Voorhees, NJ 08043 Phone: 856-325-6750 Fax: 856-325-6777 | |
Amy M Evangelisto, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2301 E. Evesham Road, Bldg 800, Suite 115, Voorhees, NJ 08043 Phone: 856-424-5005 Fax: 856-424-4716 | |
Stephen M Akers, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 900 Centennial Blvd, Suite K, Voorhees, NJ 08043 Phone: 856-325-6789 | |
Jason Palermo, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2309 E Evesham Rd, Suites 201 & 202, Voorhees, NJ 08043 Phone: 856-325-5400 Fax: 856-325-5416 | |
Dr. Robert Charles Baker, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 75 Wynnewood Dr, Voorhees, NJ 08043 Phone: 609-352-2012 Fax: 856-489-1420 | |
Dr. Eduardo Francisco Enriquez, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3 Brendenwood Dr, Voorhees, NJ 08043 Phone: 856-874-0202 Fax: 856-874-0220 | |
Arielle S. Silver, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2301 E. Evesham Road, Bldg 800, Suite 115, Voorhees, NJ 08043 Phone: 856-424-5005 Fax: 856-424-4716 |